Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.
Source Information
Surgery Branch, National Cancer Institute, Bethesda, MD 20892.
This article has been cited by other articles:
Shingler, W. H., Chikoti, P., Kingsman, S. M., Harrop, R.
(2008). Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol
20: 1057-1066
[Abstract][Full Text]
Wei, S., Shreiner, A. B., Takeshita, N., Chen, L., Zou, W., Chang, A. E.
(2008). Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor {beta}. Cancer Res.
68: 5432-5438
[Abstract][Full Text]
Chapman, P. B.
(2008). Combining a Peptide Vaccine With High-Dose Interleukin-2. JCO
26: 2250-2251
[Full Text]
Carrasco, J., Van Pel, A., Neyns, B., Lethe, B., Brasseur, F., Renkvist, N., van der Bruggen, P., van Baren, N., Paulus, R., Thielemans, K., Boon, T., Godelaine, D.
(2008). Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells. J. Immunol.
180: 3585-3593
[Abstract][Full Text]
Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P., Sanchez-Perez, L., Palmer, D. C., Yu, Z., Antony, P. A., Gattinoni, L., Rosenberg, S. A., Restifo, N. P.
(2007). Toll-like Receptors in Tumor Immunotherapy. Clin. Cancer Res.
13: 5280-5289
[Abstract][Full Text]
Sugiyama, V. E., Chan, J. K., Shin, J. Y., Berek, J. S., Osann, K., Kapp, D. S.
(2007). Vulvar Melanoma: A Multivariable Analysis of 644 Patients. Obstet Gynecol
110: 296-301
[Abstract][Full Text]
Charalambous, A., Oks, M., Nchinda, G., Yamazaki, S., Steinman, R. M.
(2006). Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin. J. Immunol.
177: 8410-8421
[Abstract][Full Text]
Markel, G., Seidman, R., Stern, N., Cohen-Sinai, T., Izhaki, O., Katz, G., Besser, M., Treves, A. J., Blumberg, R. S., Loewenthal, R., Mandelboim, O., Orenstein, A., Schachter, J.
(2006). Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions. J. Immunol.
177: 6062-6071
[Abstract][Full Text]
MacGregor, J. N., Li, Q., Chang, A. E., Braun, T. M., Hughes, D. P.M., McDonagh, K. T.
(2006). Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.. Cancer Res.
66: 4913-4921
[Abstract][Full Text]
Chan, J. K., Hamilton, C. A., Cheung, M. K., Karimi, M., Baker, J., Gall, J. M., Schulz, S., Thorne, S. H., Teng, N. N., Contag, C. H., Lum, L. G., Negrin, R. S.
(2006). Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.. Clin. Cancer Res.
12: 1859-1867
[Abstract][Full Text]
Duval, L., Schmidt, H., Kaltoft, K., Fode, K., Jensen, J. J., Sorensen, S. M., Nishimura, M. I., von der Maase, H.
(2006). Adoptive Transfer of Allogeneic Cytotoxic T Lymphocytes Equipped with a HLA-A2 Restricted MART-1 T-Cell Receptor: A Phase I Trial in Metastatic Melanoma. Clin. Cancer Res.
12: 1229-1236
[Abstract][Full Text]
Willemsen, R. A., Ronteltap, C., Chames, P., Debets, R., Bolhuis, R. L. H.
(2005). T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production. J. Immunol.
174: 7853-7858
[Abstract][Full Text]
Rosenberg, S. A.
(2005). The Emergence of Modern Cancer Immunotherapy. Ann. Surg. Oncol.
12: 344-346
[Full Text]
Zhao, Y., Zheng, Z., Robbins, P. F., Khong, H. T., Rosenberg, S. A., Morgan, R. A.
(2005). Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines. J. Immunol.
174: 4415-4423
[Abstract][Full Text]
Zhou, J., Dudley, M. E., Rosenberg, S. A., Robbins, P. F.
(2004). Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with Melanoma. J. Immunol.
173: 7622-7629
[Abstract][Full Text]
Shibuya, T. Y., Kim, S., Nguyen, K., Do, J., McLaren, C. E., Li, K.-T., Chen, W.-P., Parikh, P., Wadhwa, A., Zi, X., Chen, V. Y., Wong, H.-S., Armstrong, W. B., Yoo, G. H.
(2004). Bioactive Suture: A Novel Immunotherapy for Head and Neck Cancer. Clin. Cancer Res.
10: 7088-7099
[Abstract][Full Text]
Kershaw, M. H., Jackson, J. T., Haynes, N. M., Teng, M. W. L., Moeller, M., Hayakawa, Y., Street, S. E., Cameron, R., Tanner, J. E., Trapani, J. A., Smyth, M. J., Darcy, P. K.
(2004). Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer. J. Immunol.
173: 2143-2150
[Abstract][Full Text]
Liu, G., Ying, H., Zeng, G., Wheeler, C. J., Black, K. L., Yu, J. S.
(2004). HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells. Cancer Res.
64: 4980-4986
[Abstract][Full Text]
Bonehill, A., Heirman, C., Tuyaerts, S., Michiels, A., Breckpot, K., Brasseur, F., Zhang, Y., van der Bruggen, P., Thielemans, K.
(2004). Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules. J. Immunol.
172: 6649-6657
[Abstract][Full Text]
Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Dutton, R. W.
(2004). Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses. J. Immunol.
172: 1380-1390
[Abstract][Full Text]
Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Hylind, J. C., Dutton, R. W.
(2004). Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases. Cancer Res.
64: 406-414
[Abstract][Full Text]
Maccalli, C., Li, Y. F., El-Gamil, M., Rosenberg, S. A., Robbins, P. F.
(2003). Identification of a Colorectal Tumor-Associated Antigen (COA-1) Recognized by CD4+ T Lymphocytes. Cancer Res.
63: 6735-6743
[Abstract][Full Text]
Morgan, R. A., Dudley, M. E., Yu, Y. Y. L., Zheng, Z., Robbins, P. F., Theoret, M. R., Wunderlich, J. R., Hughes, M. S., Restifo, N. P., Rosenberg, S. A.
(2003). High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. J. Immunol.
171: 3287-3295
[Abstract][Full Text]
Feinmesser, R., Hardy, B., Sadov, R., Shwartz, A., Chretien, P., Feinmesser, M.
(2003). Report of a Clinical Trial in 12 Patients With Head and Neck Cancer Treated Intratumorally and Peritumorally With Multikine. Arch Otolaryngol Head Neck Surg
129: 874-881
[Abstract][Full Text]
Roszkowski, J. J., Yu, D. C., Rubinstein, M. P., McKee, M. D., Cole, D. J., Nishimura, M. I.
(2003). CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell. J. Immunol.
170: 2582-2589
[Abstract][Full Text]
Poehlein, C. H., Hu, H.-M., Yamada, J., Assmann, I., Alvord, W. G., Urba, W. J., Fox, B. A.
(2003). TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells. J. Immunol.
170: 2004-2013
[Abstract][Full Text]
Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R., Mackensen, A.
(2003). Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients. J. Immunol.
170: 2161-2169
[Abstract][Full Text]
Rubinstein, M. P., Kadima, A. N., Salem, M. L., Nguyen, C. L., Gillanders, W. E., Nishimura, M. I., Cole, D. J.
(2003). Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity. J. Immunol.
170: 1209-1217
[Abstract][Full Text]
Dhodapkar, M. V., Krasovsky, J., Olson, K.
(2002). T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA
99: 13009-13013
[Abstract][Full Text]
Kono, K., Takahashi, A., Ichihara, F., Amemiya, H., Iizuka, H., Fujii, H., Sekikawa, T., Matsumoto, Y.
(2002). Prognostic Significance of Adoptive Immunotherapy with Tumor-associated Lymphocytes in Patients with Advanced Gastric Cancer: A Randomized Trial. Clin. Cancer Res.
8: 1767-1771
[Abstract][Full Text]
Egilmez, N. K., Hess, S. D., Chen, F.-A., Takita, H., Conway, T. F., Bankert, R. B.
(2002). Human CD4+ Effector T Cells Mediate Indirect Interleukin-12- and Interferon-{gamma}-dependent Suppression of Autologous HLA-negative Lung Tumor Xenografts in Severe Combined Immunodeficient Mice. Cancer Res.
62: 2611-2617
[Abstract][Full Text]
Zhang, G., Li, W., Holle, L., Chen, N., Chen, W. Y.
(2002). A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer. Clin. Cancer Res.
8: 1196-1205
[Abstract][Full Text]
Leong, S. P. L., Peng, M., Zhou, Y.-M., Vaquerano, J. E., Chang, J. W. C.
(2002). Cytokine Profiles of Sentinel Lymph Nodes Draining the Primary Melanoma. Ann. Surg. Oncol.
9: 82-87
[Abstract][Full Text]
Liu, K., Rosenberg, S. A.
(2001). Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity. J. Immunol.
167: 6356-6365
[Abstract][Full Text]
Kjaergaard, J., Peng, L., Cohen, P. A., Drazba, J. A., Weinberg, A. D., Shu, S.
(2001). Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor. J. Immunol.
167: 6669-6677
[Abstract][Full Text]
Bullock, T. N. J., Mullins, D. W., Colella, T. A., Engelhard, V. H.
(2001). Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice. J. Immunol.
167: 5824-5831
[Abstract][Full Text]
Sliz, P., Michielin, O., Cerottini, J.-C., Luescher, I., Romero, P., Karplus, M., Wiley, D. C.
(2001). Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes. J. Immunol.
167: 3276-3284
[Abstract][Full Text]
Stopeck, A. T., Jones, A., Hersh, E. M., Thompson, J. A., Finucane, D. M., Gutheil, J. C., Gonzalez, R.
(2001). Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/{beta}2-Microglobulin DNA-Liposome Complex, in Patients with Metastatic Melanoma. Clin. Cancer Res.
7: 2285-2291
[Abstract][Full Text]
Jayasurya, A., Bay, B.-H., Yap, W.-M., Tan, N.-G.
(2000). Lymphocytic Infiltration in Undifferentiated Nasopharyngeal Cancer. Arch Otolaryngol Head Neck Surg
126: 1329-1332
[Abstract][Full Text]
Hu, H.-M., Winter, H., Urba, W. J., Fox, B. A.
(2000). Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy. J. Immunol.
165: 4246-4253
[Abstract][Full Text]
Schmitz, M., Diestelkoetter, P., Weigle, B., Schmachtenberg, F., Stevanovic, S., Ockert, D., Rammensee, H.-G., Rieber, E. P.
(2000). Generation of Survivin-specific CD8+ T Effector Cells by Dendritic Cells Pulsed with Protein or Selected Peptides. Cancer Res.
60: 4845-4849
[Abstract][Full Text]
Lu, J., Celis, E.
(2000). Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes. Cancer Res.
60: 5223-5227
[Abstract][Full Text]
Knappe, A., Feldmann, G., Dittmer, U., Meinl, E., Nisslein, T., Wittmann, S., Matz-Rensing, K., Kirchner, T., Bodemer, W., Fickenscher, H.
(2000). Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion. Blood
95: 3256-3261
[Abstract][Full Text]
Oelke, M., Moehrle, U., Chen, J.-L., Behringer, D., Cerundolo, V., Lindemann, A., Mackensen, A.
(2000). Generation and Purification of CD8+ Melan-A-specific Cytotoxic T Lymphocytes for Adoptive Transfer in Tumor Immunotherapy. Clin. Cancer Res.
6: 1997-2005
[Abstract][Full Text]
Panelli, M. C., Bettinotti, M. P., Lally, K., Ohnmacht, G. A., Li, Y., Robbins, P., Riker, A., Rosenberg, S. A., Marincola, F. M.
(2000). A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12. J. Immunol.
164: 4382-4392
[Abstract][Full Text]
Geoerger, B., Tang, C.-B., Cesano, A., Visonneau, S., Marwaha, S., Judy, K. D., Sutton, L. N., Santoli, D., Phillips, P. C.
(2000). Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro Oncol
2: 103-113
[Abstract]
Darcy, P. K., Haynes, N. M., Snook, M. B., Trapani, J. A., Cerruti, L., Jane, S. M., Smyth, M. J.
(2000). Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL. J. Immunol.
164: 3705-3712
[Abstract][Full Text]
Karas, M., Zaks, T. Z., JL, L., LeRoith, D.
(1999). T Cell Receptor-induced Activation and Apoptosis In Cycling Human T Cells Occur throughout the Cell Cycle. Mol. Biol. Cell
10: 4441-4450
[Abstract][Full Text]
Figlin, R. A., Thompson, J. A., Bukowski, R. M., Vogelzang, N. J., Novick, A. C., Lange, P., Steinberg, G. D., Belldegrun, A. S.
(1999). Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma. JCO
17: 2521-2521
[Abstract][Full Text]
Rongcun, Y., Salazar-Onfray, F., Charo, J., Malmberg, K.-J., Evrin, K., Maes, H., Kono, K., Hising, C., Petersson, M., Larsson, O., Lan, L., Appella, E., Sette, A., Celis3, E., Kiessling, R.
(1999). Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas. J. Immunol.
163: 1037-1044
[Abstract][Full Text]
Clay, T. M., Custer, M. C., Sachs, J., Hwu, P., Rosenberg, S. A., Nishimura, M. I.
(1999). Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity. J. Immunol.
163: 507-513
[Abstract][Full Text]
Rohrer, J. W., Barsoum, A. L., Dyess, D. L., Tucker, J. A., Coggin, J. H. Jr.
(1999). Human Breast Carcinoma Patients Develop Clonable Oncofetal Antigen-Specific Effector and Regulatory T Lymphocytes. J. Immunol.
162: 6880-6892
[Abstract][Full Text]
Valmori, D., Pittet, M. J., Rimoldi, D., Lienard, D., Dunbar, R., Cerundolo, V., Lejeune, F., Cerottini, J.-C., Romero, P.
(1999). An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer. Cancer Res.
59: 2167-2173
[Abstract][Full Text]
Maitre, N., Brown, J. M., Demcheva, M., Kelley, J. R., Lockett, M. A., Vournakis, J., Cole, D. J.
(1999). Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination. Clin. Cancer Res.
5: 1173-1182
[Abstract][Full Text]
Tanaka, H., Yoshizawa, H., Yamaguchi, Y., Ito, K., Kagamu, H., Suzuki, E., Gejyo, F., Hamada, H., Arakawa, M.
(1999). Successful Adoptive Immunotherapy of Murine Poorly Immunogenic Tumor with Specific Effector Cells Generated from Gene-Modified Tumor-Primed Lymph Node Cells. J. Immunol.
162: 3574-3582
[Abstract][Full Text]
Smith, J. A, Goldspiel, B. R
(1999). Cancer gene therapy update. J Oncol Pharm Pract
5: 7-21
[Abstract]
Clay, T. M., Custer, M. C., McKee, M. D., Parkhurst, M., Robbins, P. F., Kerstann, K., Wunderlich, J., Rosenberg, S. A., Nishimura, M. I.
(1999). Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue. J. Immunol.
162: 1749-1755
[Abstract][Full Text]
Wang, R.-F., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., Rosenberg, S. A.
(1998). A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames. J. Immunol.
161: 3596-3606
[Abstract][Full Text]
Prevost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F. M., Pircher, H.
(1998). Tumor-Infiltrating Lymphocytes Exhibiting High Ex Vivo Cytolytic Activity Fail to Prevent Murine Melanoma Tumor Growth In Vivo. J. Immunol.
161: 2187-2194
[Abstract][Full Text]
Rosendahl, A., Kristensson, K., Hansson, J., Riesbeck, K., Kalland, T., Dohlsten, M.
(1998). Perforin and IFN-{gamma} Are Involved in the Antitumor Effects of Antibody-Targeted Superantigens. J. Immunol.
160: 5309-5313
[Abstract][Full Text]
Kagamu, H., Shu, S.
(1998). Purification of L-Selectinlow Cells Promotes the Generation of Highly Potent CD4 Antitumor Effector T Lymphocytes. J. Immunol.
160: 3444-3452
[Abstract][Full Text]
Emtage, P. C. R., Wan, Y., Bramson, J. L., Graham, F. L., Gauldie, J.
(1998). A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model. J. Immunol.
160: 2531-2538
[Abstract][Full Text]
Nagoshi, M., Goedegebuure, P. S., Burger, U. L., Sadanaga, N., Chang, M. P., Eberlein, T. J.
(1998). Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes. J. Immunol.
160: 334-344
[Abstract][Full Text]
Lieberman, J., Skolnik, P. R., Parkerson III, G. R., Fabry, J. A., Landry, B., Bethel, J., Kagan, J., the DATRI 006 Study Team,
(1997). Safety of Autologous, Ex Vivo-Expanded Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Infusion in HIV-Infected Patients. Blood
90: 2196-2206
[Abstract][Full Text]
Rocha, M., Umansky, V., Lee, K.-H., Hacker, H.-J., Benner, A., Schirrmacher, V.
(1997). Differences Between Graft-Versus-Leukemia and Graft-Versus-Host Reactivity. I. Interaction of Donor Immune T Cells With Tumor and/or Host Cells. Blood
89: 2189-2202
[Abstract][Full Text]
Nabel, G. J., Gordon, D., Bishop, D. K., Nickoloff, B. J., Yang, Z.-y., Aruga, A., Cameron, M. J., Nabel, E. G., Chang, A. E.
(1996). Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA
93: 15388-15393
[Abstract][Full Text]
Wang, R.-F., Appella, E., Kawakami, Y., Kang, X., Rosenberg, S. A.
(1996). Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes. J. Exp. Med.
184: 2207-2216
[Abstract][Full Text]
Liu, C.-C., Young, L. H.Y., Young, J. D.-E
(1996). Lymphocyte-Mediated Cytolysis and Disease. NEJM
335: 1651-1659
[Full Text]
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J.-C., Tschopp, J.
(1996). Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape. Science
274: 1363-1366
[Abstract][Full Text]
Ratto, G. B., Melioli, G., Zino, P., Mereu, C., Mirabelli, S., Fantino, G., Ponte, M., Minuti, P., Verna, A., Noceti, P., Tassara, E., Rovida, S.
(1995). Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer: A pilot study. J. Thorac. Cardiovasc. Surg.
109: 1212-1217
[Abstract][Full Text]
Cox, A., Skipper, J, Chen, Y, Henderson, R., Darrow, T., Shabanowitz, J, Engelhard, V., Hunt, D., Slingluff, C. Jr
(1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science
264: 716-719
[Abstract]
Kessler, D. A., Siegel, J. P., Noguchi, P. D., Zoon, K. C., Feiden, K. L., Woodcock, J.
(1993). Regulation of Somatic-Cell Therapy and Gene Therapy by the Food and Drug Administration. NEJM
329: 1169-1173
[Full Text]
Mulligan, R.
(1993). The basic science of gene therapy. Science
260: 926-932
[Abstract]
Lanzavecchia, A
(1993). Identifying strategies for immune intervention. Science
260: 937-944
[Abstract]
Takahashi, H, Nakada, T, Puisieux, I
(1993). Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science
259: 1460-1463
[Abstract]
Anderson, W.
(1992). Human gene therapy. Science
256: 808-813
[Abstract]
(1988). PROMISING IMMUNOTHERAPEUTIC ADVANCE IN CANCER. JWatch General
1988: 6-6
[Full Text]
Previous
